Compare Elder Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA IPCA LABS ELDER PHARMA/
IPCA LABS
 
P/E (TTM) x -0.2 22.9 - View Chart
P/BV x 0.1 4.4 2.3% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ELDER PHARMA   IPCA LABS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
IPCA LABS
Mar-18
ELDER PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs380695 54.6%   
Low Rs188400 47.0%   
Sales per share (Unadj.) Rs491.2260.2 188.8%  
Earnings per share (Unadj.) Rs-3.219.0 -16.8%  
Cash flow per share (Unadj.) Rs14.433.1 43.6%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs376.5213.0 176.7%  
Shares outstanding (eoy) m20.54126.20 16.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.62.1 27.5%   
Avg P/E ratio x-89.328.9 -309.2%  
P/CF ratio (eoy) x19.716.6 119.0%  
Price / Book Value ratio x0.82.6 29.3%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m5,83369,120 8.4%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1797,359 29.6%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m10,08932,836 30.7%  
Other income Rs m257418 61.4%   
Total revenues Rs m10,34633,254 31.1%   
Gross profit Rs m-7924,505 -17.6%  
Depreciation Rs m3611,777 20.3%   
Interest Rs m2,756240 1,147.5%   
Profit before tax Rs m-3,6532,905 -125.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125511 24.5%   
Profit after tax Rs m-652,394 -2.7%  
Gross profit margin %-7.813.7 -57.2%  
Effective tax rate %-3.417.6 -19.5%   
Net profit margin %-0.67.3 -8.9%  
BALANCE SHEET DATA
Current assets Rs m9,24019,455 47.5%   
Current liabilities Rs m9,99810,076 99.2%   
Net working cap to sales %-7.528.6 -26.3%  
Current ratio x0.91.9 47.9%  
Inventory Days Days4698 47.3%  
Debtors Days Days6067 89.5%  
Net fixed assets Rs m10,12420,260 50.0%   
Share capital Rs m206252 81.5%   
"Free" reserves Rs m5,58226,633 21.0%   
Net worth Rs m7,73426,886 28.8%   
Long term debt Rs m4,8892,340 208.9%   
Total assets Rs m22,88241,173 55.6%  
Interest coverage x-0.313.1 -2.5%   
Debt to equity ratio x0.60.1 726.3%  
Sales to assets ratio x0.40.8 55.3%   
Return on assets %11.86.4 183.8%  
Return on equity %-0.88.9 -9.5%  
Return on capital %22.310.8 207.3%  
Exports to sales %3.047.6 6.4%   
Imports to sales %0.414.9 2.9%   
Exports (fob) Rs m30715,642 2.0%   
Imports (cif) Rs m434,884 0.9%   
Fx inflow Rs m30715,642 2.0%   
Fx outflow Rs m1254,884 2.6%   
Net fx Rs m18110,759 1.7%   
CASH FLOW
From Operations Rs m11,7543,411 344.6%  
From Investments Rs m-561-1,354 41.4%  
From Financial Activity Rs m-6,762-1,304 518.5%  
Net Cashflow Rs m4,432753 588.4%  

Share Holding

Indian Promoters % 39.6 45.9 86.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 16.8 25.3 66.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.4 207.5%  
Shareholders   16,479 36,892 44.7%  
Pledged promoter(s) holding % 77.6 2.1 3,624.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS